In the latest session, Humana Inc. (NYSE: HUM) closed at $339.08 up 0.34% from its previous closing price of $337.92. In other words, the price has increased by $+1.16 from its previous closing price. On the day, 1551248 shares were traded.
Ratios:
For a deeper understanding of Humana Inc.’s stock, let’s take a closer look at its various ratios. In the meantime, Its Debt-to-Equity ratio is 0.75 whereas as Long-Term Debt/Eq ratio is at 0.66.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Barclays on Mar-07-24, initiated with a Equal Weight rating and assigned the stock a target price of $356.
On January 26, 2024, Cantor Fitzgerald Downgraded its rating to Neutral which previously was Overweight but kept the price unchanged to $391.
Deutsche Bank Downgraded its Buy to Hold on January 25, 2024, while the target price for the stock was maintained at $360.
Insider Transactions:
Additionally, insider trades can be beneficial to investors who want to learn what the management thinks about stock prices in the future. A recent insider transaction in this stock occurred on Feb 20 ’24 when Mesquita Jorge S. bought 545 shares for $367.09 per share. The transaction valued at 200,066 led to the insider holds 2,578 shares of the business.
Diamond Susan M sold 4,156 shares of HUM for $2,187,226 on May 04 ’23. The Chief Financial Officer now owns 3,931 shares after completing the transaction at $526.28 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HUM now has a Market Capitalization of 40.91B and an Enterprise Value of 48.23B. As of this moment, Humana’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.10, and their Forward P/E ratio for the next fiscal year is 13.90. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 3.29. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.38 while its Price-to-Book (P/B) ratio in mrq is 2.55. Its current Enterprise Value per Revenue stands at 0.45.
Stock Price History:
Over the past 52 weeks, HUM has reached a high of $541.21, while it has fallen to a 52-week low of $337.14. The 50-Day Moving Average of the stock is 399.13, while the 200-Day Moving Average is calculated to be 462.29.
Shares Statistics:
For the past three months, HUM has traded an average of 2.07M shares per day and 1.66M over the past ten days. A total of 122.22M shares are outstanding, with a floating share count of 120.22M. Insiders hold about 0.36% of the company’s shares, while institutions hold 94.51% stake in the company. Shares short for HUM as of Feb 15, 2024 were 2.16M with a Short Ratio of 1.05, compared to 2.12M on Jan 12, 2024. Therefore, it implies a Short% of Shares Outstanding of 1.79% and a Short% of Float of 1.80%.
Dividends & Splits
According to the company, the forward annual dividend rate for HUM is 3.54, from 3.54 in the trailing year. Against a Trailing Annual Dividend Yield of 1.05%, it implies a Forward Annual Dividend Yield of 1.04%. The stock’s 5-year Average Dividend Yield is 0.67. The current Payout Ratio is 17.70% for HUM, which recently paid a dividend on Apr 26, 2024 with an ex-dividend date of Mar 27, 2024. Stock splits for the company last occurred on Aug 01, 1991 when the company split stock in a 3:2 ratio.
Earnings Estimates
There are 17 different market analysts currently analyzing its stock. On average, analysts expect EPS of $6.18 for the current quarter, with a high estimate of $8.11 and a low estimate of $5.82, while EPS last year was $9.38. The consensus estimate for the next quarter is $5.92, with high estimates of $8.12 and low estimates of $4.31.
Analysts are recommending an EPS of between $18.84 and $16 for the fiscal current year, implying an average EPS of $16.38. EPS for the following year is $24.78, with 17 analysts recommending between $28.23 and $23.28.
Revenue Estimates
A total of 15 analysts believe the company’s revenue will be $28.35B this quarter.It ranges from a high estimate of $29.6B to a low estimate of $27.44B. As of the current estimate, Humana Inc.’s year-ago sales were $25.65B, an estimated increase of 10.50% from the year-ago figure. For the next quarter, 15 analysts are estimating revenue of $27.98B, an increase of 8.70% less than the figure of $10.50% in the same quarter last year. There is a high estimate of $28.61B for the next quarter, whereas the lowest estimate is $27.35B.
A total of 15 analysts have provided revenue estimates for HUM’s current fiscal year. The highest revenue estimate was $113.64B, while the lowest revenue estimate was $108.91B, resulting in an average revenue estimate of $111.47B. In the same quarter a year ago, actual revenue was $102.64B, up 8.60% from the average estimate. Based on 14 analysts’ estimates, the company’s revenue will be $116.31B in the next fiscal year. The high estimate is $123.94B and the low estimate is $109.52B. The average revenue growth estimate for next year is up 4.30% from the average revenue estimate for this year.
